United Therapeutics (UTHR): insider & executive buying
United Therapeutics · Health Care · ref. ETF XLV · price $527.91
In short — 1 insider bought United Therapeutics over ~6 months (1 buy, total $864k, latest May 26, 26). Public Form 4 data, informative (not a performance signal).
Are United Therapeutics's executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$527.91+71.8% over range
Aug 28, 25low $304.76 · high $596.76Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
78% recommend buying · 9 analysts
Latest insider buys on United Therapeutics
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| May 26, 26 | Rothblatt Martine A | CHAIRPERSON, CEO | 1,500 | $864k |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have United Therapeutics's executives bought shares recently?
1 United Therapeutics insider(s) bought $864k over ~6 months (latest May 26, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for UTHR?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about United Therapeutics? The JPI assistant answers using our backtest data.
Keep exploring United Therapeutics